International Myeloma Society Annual Meeting | Conference

Isatuximab Plus Kd Demonstrates Deep Responses in Relapsed Multiple Myeloma

August 27th 2022

The addition of isatuximab to carfilzomib and dexamethasone elicited a clinically meaningful improvement in depth of response in patients with relapsed multiple myeloma.

REGN5458 Elicits Promising Responses, Safety in Relapsed/Refractory Myeloma

August 27th 2022

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data

August 27th 2022

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

Dr. Richardson on Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma

August 27th 2022

Paul G. Richardson, MD, discusses the overall survival benefit displayed by isatuximab plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.

Dr. Puertas‐Martinez on Carfilzomib and Dexamethasone plus Cyclophosphamide in Multiple Myeloma

August 27th 2022

Borja Puertas‐Martinez, MD, discusses the use of carfilzomib and dexamethasone with or without cyclophosphamide in patients with relapsed/refractory multiple myeloma.

Cevostamab Elicits Responses in Younger and Older Patients with Relapsed/Refractory Myeloma

August 27th 2022

Cevostamab generated responses and was well tolerated in younger and older patients with relapsed/refractory multiple myeloma.

Ocular Toxicity With Belantamab Mafodotin Is Not Influenced by Baseline Ocular Conditions in R/R Myeloma

August 27th 2022

Baseline ocular conditions not related to the cornea have little effect on treatment-emergent adverse effects that may arise with belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Isatuximab Under Evaluation in Real-World Study in Relapsed/Refractory Multiple Myeloma

August 27th 2022

Treatment with standard-of-care isatuximab in patients with relapsed/refractory multiple myeloma is being evaluated in a real-world trial,

Post-Transplant Carfilzomib Plus Lenalidomide/Dexamethasone Provides Superior PFS Benefit Over Lenalidomide in Myeloma

August 26th 2022

Extended treatment with carfilzomib plus lenalidomide and dexamethasone after autologous stem cell transplant improved progression-free survival over standard lenalidomide maintenance in patients with multiple myeloma.

Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma

August 26th 2022

The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26th 2022

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

Long-Term Treatment with Daratumumab Plus Lenalidomide/Dexamethasone Boosts OS Benefits in Myeloma

August 26th 2022

Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.

Dr. Sklavenitis-Pistofidis on Single-Cell Dissection of Immune Cells in Smoldering Myeloma

August 26th 2022

Romanos Sklavenitis-Pistofidis, MD, discusses single-cell dissection of bone marrow and peripheral blood immune cells in smoldering multiple myeloma.

Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple Myeloma

August 26th 2022

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Daratumumab Plus KRd Induction and Consolidation With Tandem Transplant Has Feasibility in High-Risk Newly Diagnosed Myeloma

August 26th 2022

Induction and consolidation therapy with a combination comprised of daratumumab, carfilzomib, lenalidomide, and dexamethasone allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant.

Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma

August 26th 2022

Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.

Isatuximab-Based Regimens Demonstrate Favorable Safety in Relapsed/Refractory Multiple Myeloma

August 26th 2022

Isatuximab-containing regimens displayed favorable toxicity in patients with relapsed/refractory multiple myeloma in a real-world study.

Targeted Therapies Continue to Shift Treatment Armamentarium in Multiple Myeloma

August 26th 2022

Patient outcomes across the multiple myeloma landscape have vastly improved with the approval of multiple agents in the treatment armementarium, such as belantamab mafodotin-blmf, selinexor, and ciltacabtagene autoleucel.

Ixazomib Regimen Induces High Response Rates, Proves Tolerable in Relapsed/Refractory Multiple Myeloma

August 26th 2022

The addition of ixazomib to daratumumab, pomalidomide, and dexamethasone has elicited deep and durable response rates with a manageable safety profile as salvage therapy in patients with relapsed/refractory multiple myeloma.

Talquetamab Adverse Event Management in Myeloma Requires Early Oral, Dermatologic Interventions

August 25th 2022

Patients with multiple myeloma can mitigate the common oral and dermatologic toxicities associated with talquetamab with early intervention tactics.